【專利讓與】Method for inhibiting activation of macrophages(用於抑制巨噬細胞活化之醫藥組合物及其用途)

中國醫藥大學 研發成果讓與公告

本校案件

科技部成果公告讓與

公告日期

2020/9/1

發明人代表

中國醫藥大學 藥學系 林文川老師

專利(技術)名稱

Method for inhibiting activation of macrophages

專利國別

美國

專利核准日

2013.10.29

專利證號

US 8,569,249 B2

類型

發明

專利範圍

(英文)

1. A method for inhibiting the activation of macrophages in a subject, comprising administering to the subject in need thereof, an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and combinations thereof: ##STR00005## and wherein the dosage of said administering is selected to effectively treat arthritis or hepatitis.

2. The method as claimed in claim 1, wherein the subject has rheumatoid arthritis.

3. The method as claimed in claim 1, further comprising: wherein the active component is administered as a pharmaceutical composition.

4. The method as claimed in claim 1, wherein the active component is administered by oral administration, subcutaneous injection, intravenous injection, or intra-articular injection.

5. The method as claimed in claim 1, wherein the active component is the compound of formula (I).

6. A method for treating inflammation in a subject, comprising administering to the subject in need thereof, an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and combinations thereof: ##STR00006##

7. The method as claimed in claim 6, further comprising: wherein the active component is administered as a pharmaceutical composition.

8. The method as claimed in claim 6, wherein the active component is administered by oral administration, subcutaneous injection, intravenous injection, or intra-articular injection.

9. The method as claimed in claim 6, wherein the active component is the compound of formula (I).

專利範圍

1.一種使用一活性成分在製造抑制巨噬細胞活化之藥物的用途,其中該活性成分係選自以下群組之至少一者:式(I)化合物及其醫藥上可接受鹽:

2.如請求項1之用途,其中該活性成分係式(I)化合物。

3.如請求項1或2之用途,其中該藥物係用於選自以下群組之至少一者:治療巨噬細胞活化綜合症(macrophage activation syndrome,MAS)、治療或抑制發炎、及抑制基質金屬蛋白酶-9(matrix metalloproteinase-9,MMP-9)之表現。

4.如請求項3之用途,其中該藥物係用於抑制基質金屬蛋白酶-9之表現。

5.如請求項3之用途,其中該藥物係用於治療關節炎及肝炎之至少一者。

6.如請求項5之用途,其中該藥物係用於治療風濕性關節炎(rheumatoid arthritis)。

7.如請求項4之用途,其中該藥物係用於抑制選自以下群組之至少一者:腫瘤細胞之增生、腫瘤細胞之遷移、及腫瘤細胞之侵入。

8.如請求項7之用途,其中該腫瘤細胞係選自以下群組:骨肉瘤細胞、肉瘤細胞、淋巴瘤細胞、前列腺癌細胞、神經膠母細胞瘤細胞、黑色素癌細胞、肺癌細胞、胰臟癌細胞、卵巢癌細胞、乳癌細胞、及其組合。

發佈留言

發佈留言必須填寫的電子郵件地址不會公開。 必填欄位標示為 *